 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
0 News |  |
- |||| camoteskimab (AVTX-007) / Apollo Therap
New P2 trial: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - May 30, 2024
P2, N=60, Recruiting, Sponsor: Apollo Therapeutics Ltd
- camoteskimab (AVTX-007) / Apollo Therap
Phase classification: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 29, 2024
P1, N=13, Completed, Sponsor: Avalo Therapeutics, Inc.
Phase classification: P1b --> P1
- camoteskimab (AVTX-007) / Apollo Therap
Phase classification, Enrollment change, Trial termination: A Study to Evaluate Camoteskimab in Participants With Still's Disease (clinicaltrials.gov) - Aug 23, 2023
P1b, N=5, Terminated, Sponsor: Apollo Therapeutics Ltd
Phase classification: P1b --> P1 Phase classification: P1b/2a --> P1b | N=20 --> 5 | Recruiting --> Terminated; Sponsor discretion
- ||| camoteskimab (AVTX-007) / Apollo Therap
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate Camoteskimab in Participants With Still's Disease (clinicaltrials.gov) - Mar 15, 2023
P1b/2a, N=20, Recruiting, Sponsor: Apollo Therapeutics Ltd
Phase classification: P1b/2a --> P1b | N=20 --> 5 | Recruiting --> Terminated; Sponsor discretion Phase classification: P1b --> P1b/2a | N=12 --> 20 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024
- | camoteskimab (AVTX-007) / Apollo Therap
Trial completion date, Trial primary completion date: A Study to Evaluate Camoteskimab in Participants With Still's Disease (clinicaltrials.gov) - Aug 31, 2022
P1b, N=12, Recruiting, Sponsor: Apollo Therapeutics Ltd
Phase classification: P1b --> P1b/2a | N=12 --> 20 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024 Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Mar 2022 --> Sep 2023
- || AVTX-007 / Avalo Therap
$AVTX Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics https://t.co/PSjsbd4We4 (Twitter) - Aug 1, 2022
- | camoteskimab (AVTX-007) / Apollo Therap
Trial completion, Enrollment change, Trial completion date: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - May 4, 2022
P1b, N=13, Completed, Sponsor: Avalo Therapeutics, Inc.
Trial completion date: Mar 2022 --> Dec 2023 | Trial primary completion date: Mar 2022 --> Sep 2023 Recruiting --> Completed | N=30 --> 13 | Trial completion date: Jun 2022 --> Mar 2022
- | camoteskimab (AVTX-007) / Apollo Therap
Trial completion date, Trial primary completion date: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 4, 2022
P1b, N=30, Recruiting, Sponsor: Cerecor Inc
Recruiting --> Completed | N=30 --> 13 | Trial completion date: Jun 2022 --> Mar 2022 Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Mar 2022
- ||||| CERC-007 / Cerecor
Clinical, Launch Europe, Launch US: Cerecor has launched a c Phase 1b clinical trial (NCT04752371) of the human mAb CERC-007, targeting IL-18, in 12 patients with active adult onset Still’s disease (AOSD). They estimate AOSD affects 3,500 - 7,000 in the US 3,400 - 6,900 pts in Europe https://t.co/DlW1QbXOG0 (Twitter) - May 14, 2021
P1b
- || camoteskimab (AVTX-007) / Apollo Therap
Enrollment open: A Study to Evaluate Camoteskimab in Participants With Still's Disease (clinicaltrials.gov) - Apr 20, 2021
P1b, N=12, Recruiting, Sponsor: Cerecor Inc
Trial completion date: Aug 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- || camoteskimab (AVTX-007) / Apollo Therap
New P1 trial: A Study to Evaluate Camoteskimab in Participants With Still's Disease (clinicaltrials.gov) - Feb 11, 2021
P1b, N=12, Not yet recruiting, Sponsor: Cerecor Inc
- || camoteskimab (AVTX-007) / Apollo Therap
Enrollment open: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 19, 2020
P1b, N=30, Recruiting, Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || camoteskimab (AVTX-007) / Apollo Therap
New P1 trial: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 16, 2020
P1b, N=30, Not yet recruiting, Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company
- | camoteskimab (AVTX-007) / Apollo Therap
Trial completion: A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - May 9, 2012
P1, N=31, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Recruiting --> Completed